244 related articles for article (PubMed ID: 33229355)
1. [Not Available].
Ye Z; Wang Y; Colunga-Lozano LE; Prasad M; Tangamornsuksan W; Rochwerg B; Yao L; Motaghi S; Couban RJ; Ghadimi M; Bala MM; Gomaa H; Fang F; Xiao Y; Guyatt GH
CMAJ; 2020 Nov; 192(47):E1571-E1584. PubMed ID: 33229355
[TBL] [Abstract][Full Text] [Related]
2. Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.
Sukhdeo S; Negroponte E; Rajasekhar H; Gaur S; Horton DB; Malhotra A; Moorthy LN
Lupus; 2021 Apr; 30(5):836-839. PubMed ID: 33509065
[TBL] [Abstract][Full Text] [Related]
3. The Role of Glucocorticoids in the Management of COVID-19.
Alexaki VI; Henneicke H
Horm Metab Res; 2021 Jan; 53(1):9-15. PubMed ID: 33207372
[TBL] [Abstract][Full Text] [Related]
4. A Case Report for Using Methylprednisolone for Severe ARDS Caused by SARS-CoV-2 Delta Variant in a Pediatric Patient With Lennox-Gastaut Syndrome.
Park E; You J
J Korean Med Sci; 2022 Mar; 37(10):e82. PubMed ID: 35289141
[TBL] [Abstract][Full Text] [Related]
5. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
Caocci G; La Nasa G
Ann Hematol; 2020 Jul; 99(7):1675-1676. PubMed ID: 32405693
[No Abstract] [Full Text] [Related]
6. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
Cadegiani FA
Am J Physiol Endocrinol Metab; 2020 May; 318(5):E587-E588. PubMed ID: 32297520
[No Abstract] [Full Text] [Related]
7. Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.
Ting CT; Chen BS
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409008
[TBL] [Abstract][Full Text] [Related]
8. AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm.
Gangemi S; Tonacci A
Cytokine Growth Factor Rev; 2021 Apr; 58():111-113. PubMed ID: 32938545
[TBL] [Abstract][Full Text] [Related]
9. Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury.
Tabassum N; Zhang H; Stebbing J
Cell Rep Med; 2020 Nov; 1(8):100145. PubMed ID: 33225317
[TBL] [Abstract][Full Text] [Related]
10. Is dexamethasone an effective treatment for severe COVID-19 patients: Journal Club review.
Chan K; Sharif S; Rochwerg B
CJEM; 2021 Mar; 23(2):159-161. PubMed ID: 33534117
[No Abstract] [Full Text] [Related]
11. COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan.
Zhou X; Bai T; Meckel K; Song J; Jin Y; Kortüm KM; Einsele H; Hou X; Rasche L
Ann Hematol; 2021 Mar; 100(3):843-846. PubMed ID: 32683456
[No Abstract] [Full Text] [Related]
12. Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic.
Noreen S; Maqbool I; Madni A
Eur J Pharmacol; 2021 Mar; 894():173854. PubMed ID: 33428898
[TBL] [Abstract][Full Text] [Related]
13. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?
Bendjelid K; Giraud R; Von Düring S
Anaesth Crit Care Pain Med; 2020 Aug; 39(4):451-452. PubMed ID: 32653550
[No Abstract] [Full Text] [Related]
14. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).
Altschuler EL; Kast RE
Med Hypotheses; 2020 Aug; 141():109774. PubMed ID: 32344275
[No Abstract] [Full Text] [Related]
15. Methadone as a rescue drug for difficult-to-sedate critically ill patients suffering from ARDS related to SARS-CoV-2 infection.
Fernández-Tobar R; Chamorro-Jambrina C; Pérez-Torres M; Castiñeiras-Amor B; Alcántara-Carmona S; Romera-Ortega MA
Med Intensiva (Engl Ed); 2022 May; 46(5):279-281. PubMed ID: 35292199
[No Abstract] [Full Text] [Related]
16. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.
Caracciolo M; Macheda S; Labate D; Tescione M; La Scala S; Vadalà E; Squillaci R; D'Aleo F; Morabito A; Garreffa C; Marciano MC; Oliva EN
Front Immunol; 2020; 11():1942. PubMed ID: 32983123
[TBL] [Abstract][Full Text] [Related]
17. Effect of Positive End-Expiratory Pressure and Proning on Ventilation and Perfusion in COVID-19 Acute Respiratory Distress Syndrome.
Perier F; Tuffet S; Maraffi T; Alcala G; Victor M; Haudebourg AF; De Prost N; Amato M; Carteaux G; Mekontso Dessap A
Am J Respir Crit Care Med; 2020 Dec; 202(12):1713-1717. PubMed ID: 33075235
[No Abstract] [Full Text] [Related]
18. Ventilatory weaning and early rehabilitation in COVID-19-related acute respiratory distress syndrome: the experience at Locarno hospital, canton of Ticino, Switzerland.
Forni R; Besana T; Amitrano A; Voinea C; Ogna A
Swiss Med Wkly; 2020 Nov; 150():w20397. PubMed ID: 33180953
[No Abstract] [Full Text] [Related]
19. Audio Interview: Tocilizumab and Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
[No Abstract] [Full Text] [Related]
20. SARS-CoV-2 multisystem inflammatory syndrome in an adult presenting with polyarthritis treated with anakinra.
Chalasani V; Parameswaran P; Cherico A; Villgran V; Lowther H; Marco J
Rheumatology (Oxford); 2022 Feb; 61(2):e33-e34. PubMed ID: 34508552
[No Abstract] [Full Text] [Related]
[Next] [New Search]
